Boundless Bio, Inc. (BOLD)

Boundless Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	19.49	18	12.16	9.31	6.02
Research & Development	48.34	55.27	42.64	37.16	19.28
Total Operating Expenses	67.83	73.27	54.8	46.47	25.3
Operating Income	-67.83	-73.27	-54.8	-46.47	-25.3
Interest Income	6.16	7.89	5.28	0.67	0.1
Other Non-Operating Income (Expense)	-0.09	0.01	0.08	0.1	0.01
Total Non-Operating Income (Expense)	6.07	7.9	5.36	0.57	0.09
Pretax Income	-61.76	-65.36	-49.43	-45.9	-25.21
Net Income	-61.76	-65.36	-49.43	-45.9	-25.21
Net Income to Common	-61.76	-65.36	-49.43	-45.9	-25.21
Shares Outstanding (Basic)	22	17	1	1	1
Shares Outstanding (Diluted)	22	17	1	1	1
Shares Change (YoY)	90.95%	1296.71%	10.75%	27.59%	-
EPS (Basic)	-2.77	-3.85	-40.65	-41.80	-29.25
EPS (Diluted)	-2.77	-3.85	-40.65	-41.80	-29.25
Free Cash Flow	-52.71	-63.38	-47.49	-40.66	-25.28
Free Cash Flow Per Share	-2.36	-3.73	-39.05	-37.03	-29.38
EBITDA	-66.59	-72.18	-53.84	-45.53	-24.62
EBIT	-67.83	-73.27	-54.8	-46.47	-25.3

Updated Nov 5, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q